BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

21 related articles for article (PubMed ID: 20712953)

  • 1. Overexpression of CTEN is associated with gefitinib resistance in non-small cell lung cancer.
    Lu X; Zhang Y; Pan Y; Cao M; Zhou X; Zhang T
    Oncol Lett; 2021 Jan; 21(1):40. PubMed ID: 33262832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
    Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
    Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro.].
    Wei W; Fan Y; Liu H; Wu Z; Wan H; Yan Z; Xu K; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2009 Jan; 12(1):28-32. PubMed ID: 20712953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
    Ju LX; Zhou CC; Tang L; Zhao YM; Yang XJ; Su B; Meng SY; Li W; Yan LH; Ding YM
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 May; 33(5):354-8. PubMed ID: 20646614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
    Qin X; Liu B; Li Y; You J; Zhou Q
    Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):478-83. PubMed ID: 21645449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway.
    Song YA; Ma T; Zhang XY; Cheng XS; Olajuyin AM; Sun ZF; Zhang XJ
    Cancer Cell Int; 2019; 19():117. PubMed ID: 31073278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway.
    Wang B; Jiang H; Wang L; Chen X; Wu K; Zhang S; Ma S; Xia B
    Oncol Lett; 2017 May; 13(5):3494-3500. PubMed ID: 28529576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [VEGF-D expression in lung adenocarcinoma with or without acquired resistance to gefitinib and normal lung tissue].
    Wang Z; Wu Y; Zhang G; Guo A; Su J; Chen Z
    Zhongguo Fei Ai Za Zhi; 2007 Dec; 10(6):477-80. PubMed ID: 21129303
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.